Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,280 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Adenovirus Infection
Interventions: CTL administration; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Houston, Texas

Conditions: COVID-19, SARS-CoV 2
Interventions: Povidone-Iodine Nasal Spray and Gargle; Drug
Lead sponsor: Nikita Gupta; Other
Eligibility: 18 Years to 99 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Influenza, Healthy
Interventions: Monovalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Stockbridge, Georgia • Portland, Oregon

Conditions: COVID, Coronavirus, Coronavirus Infection, AKI, Acute Kidney Injury
Interventions: Sodium bicarbonate, Standard of Care; Drug · Other
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Infection
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Post Operative Surgical Site Infection
Interventions: Treatment group, Control group; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • Redwood City, California + 35 more

Conditions: Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions: Fluconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: HORIZONS HIV Intervention, enhanced standard-of-care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 15 Years to 21 Years · Female only
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Rabies
Interventions: SYN023, HRIG (HyperRab), Rabies vaccine; Biological
Lead sponsor: Synermore Biologics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Gainesville, Florida • Iowa City, Iowa • Milan, Tennessee + 2 more

Conditions: Common Cold
Interventions: 3804-250A, 3804-291; Drug
Lead sponsor: The Dial Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Paramus, New Jersey • Charlottesville, Virginia

Conditions: Cytomegalovirus Infections
Interventions: maribavir, placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 56
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 42 more

Conditions: Colonization
Interventions: Povidone-Iodine, Chlorhexidine, Pluronic, Control; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: Up to 7 Days
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetic Foot Ulcer
Interventions: gentamicin-collagen sponge, placebo collagen sponge; Drug
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pasadena, Maryland

Conditions: Sexually Transmitted Infections
Interventions: 60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling., 20-Min education session; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: E Coli Infections, Allogenic Transplant Patients
Interventions: SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL; Biological · Other
Lead sponsor: SNIPR Biome Aps.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Duarte, California • San Francisco, California • Baltimore, Maryland + 6 more

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, LNG/EE; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Diarrhea Travelers, Antibiotic Resistant Infection
Interventions: Bismuth subsalicylate, Placebo; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: COPD, Chronic Bronchitis, Emphysema
Interventions: pneumatic vest, placebo pneumatic vest; Device · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19, SARS-CoV-2
Interventions: Azithromycin, Placebos; Drug
Lead sponsor: Thomas M. Lietman; Other
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthcare-Associated Pneumonia
Interventions: Oral Hygiene - teeth brushing; Other
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8,709 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Group B Streptococcal Infection
Interventions: Vaginal and rectovaginal swab cultures; Biological
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: HIV, Sexually Transmitted Infections
Interventions: Latino STYLE; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 14 Years and older
Enrollment: 542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Surgical Site Infection, Vancomycin
Interventions: Administration of Vancomycin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV
Interventions: Social Network Intervention, Counsel, Test, and Treat; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio • Milwaukee, Wisconsin

Search by objective public record fields.

Administration of Virus-Specific Cytotoxic T-Lymphocytes

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season

Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization

Antibiotic Prophylaxis Before Percutaneous Gastrostomy

Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

HORIZONS HIV Intervention

Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients

Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections

Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer

Brief HIV Prevention Counseling for STI Patients in South Africa

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

Hospital-acquired Pneumonia Prevention: Intervention, Evaluation & Research

Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization

Randomized Control Trial of Family-Based HIV Prevention for Latinos

Pharmacokinetics of Preoperative Vancomycin

Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)